Auto-immune

Delve into the world of Auto-immune in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on Auto-immune to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

European Commission Approves AbbVie's RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor
CompanyDrug

European Commission Approves AbbVie’s RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor

AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has approved RINVOQ (upadacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients aged 2 years and…

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly's Foundayo

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly’s Foundayo

Asieris Doses First Patient in Phase I/II Trial of APL‑2501 – Anti‑CLDN6/9 ADC Advances Toward Ovarian, Lung, Endometrial and Gastric Cancers

Asieris Doses First Patient in Phase I/II Trial of APL‑2501 – Anti‑CLDN6/9 ADC Advances Toward Ovarian, Lung, Endometrial and Gastric Cancers

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Biosion’s Bosakitug Shows Positive Results in Atopic Dermatitis Phase II POC Study

CompanyDrug

JW Therapeutics Presents Positive Clinical Data for Carteyva in SLE at EULAR 2024

CompanyDeals

Johnson & Johnson to Acquire Atopic Dermatitis Therapy NM26 in $1.25 Billion Deal

CompanyDrug

Novartis’ Fabhalta Shows Promise in Late-Stage C3 Glomerulopathy Trial

CompanyDrug

Roche’s Genentech Gets Green Light for Vixarelimab UC Clinical Trial in China

CompanyDrug

Changchun High & New Technology Industries Gets Green Light for Jinnamab Clinical Trial

CompanyDrug

BMS’s Sotyktu Sustains Clinical Response in Long-Term Psoriasis Treatment

CompanyDeals

J&J Acquires Immune-Mediated Diseases Specialist Proteologix in a Deal Worth Up to USD 850 Million

Show More